Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum, particularly with Baqsimi, which saw a significant approximately 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, aided by seasonal factors and collaborative sales efforts. The company anticipates a return to double-digit growth starting in 2026, with expectations of high-single-digit unit growth for Baqsimi in 2025, which positions Amphastar favorably against its peers in terms of revenue and price-to-earnings ratios. Additionally, products like Primatene Mist have performed strongly, indicating robust demand that may further support the company's financial growth in the upcoming seasons.

Bears say

Amphastar Pharmaceuticals Inc is experiencing significant challenges in its revenue projections due to increased competition and supply issues affecting its products, particularly iron sucrose and glucagon, with expected sales declining to below $70 million in the upcoming years. The competition landscape has evolved from a sole player to a four-player market for glucagon, leading to moderated growth expectations, with top-line growth forecasts downgraded from double digits to high-single digits or low double digits for 2026. Consequently, these developments indicate ongoing pressure on Amphastar's sales and may adversely impact the company's financial stability moving forward.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.